Table 3 RCA-CVVHD flows and citrate dose at start of treatment and end of observation
|  | Normal liver function (bilirubin ≤2 mg/dl) | Mild liver failure (bilirubin 2–7 mg/dl) | Severe liver failure (bilirubin ≥7 mg/dl) | |||
|---|---|---|---|---|---|---|
Start | End | Start | End | Start | End | |
Blood flow (ml/min) | 109 ± 24 | 114 ± 25 | 109 ± 25 | 117 ± 28 | 110 ± 24 | 107 ± 20 |
Dialysate flow (ml/h) | 2144 ± 502 | 2292 ± 500 | 2128 ± 405 | 2328 ± 567 | 2098 ± 403 | 2319 ± 501 |
Net ultrafiltration (ml/h) | 77 ± 108 | 74 ± 114 | 68 ± 100 | 84 ± 105 | 84 ± 103 | 85 ± 102 |
Citrate dose (mmol/L blood) | 4.0 ± 0.1 | 3.8 ± 0.2 | 4.0 ± 0.1 | 3.9 ± 0.3 | 4.0 ± 0.1 | 4.1 ± 0.4 |